Home Biosimilar Antibodies Others Others antibody Navicixizumab (Anti-DLL4) For research use only.
Not for use in humans.

Navicixizumab (Anti-DLL4)

Synonyms: OMP-305B83; Anti-DLL4 Reference Antibody 

Navicixizumab (Anti-DLL4) is a bispecific monoclonal antibody targeting DLL4. Navicixizumab can combine with Paclitaxel for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer. MW: 145.5 KD.

Navicixizumab (Anti-DLL4)

Purity & Quality Control

≥99

Biological Activity

Description Navicixizumab (Anti-DLL4) is a bispecific monoclonal antibody targeting DLL4. Navicixizumab can combine with Paclitaxel for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer. MW: 145.5 KD.

Product Details

CAS No. 1638338-43-8
Molecular Weight 145.5 kDa
Isotype Human IgG2SA
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100mMPro-Ac,20mMArg-Ac，pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Navicixizumab (Anti-DLL4) | Navicixizumab (Anti-DLL4) supplier | purchase Navicixizumab (Anti-DLL4) | Navicixizumab (Anti-DLL4) cost | Navicixizumab (Anti-DLL4) manufacturer | order Navicixizumab (Anti-DLL4) | Navicixizumab (Anti-DLL4) distributor